Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings, the program is now being expanded beyond solid tumors to also include chronic kidney disease.
The study, conducted in an established animal model of chronic kidney disease, shows that a compound from Sprint Bioscience's NNMT program exhibits a pronounced antifibrotic effect. These results are fully consistent with several recently published scientific reports from independent research groups, confirming that NNMT inhibition positively affects disease progression in CKD animal models.
Chronic kidney disease frequently develops as a consequence of diabetes or hypertension and remains one of the leading causes of kidney transplantation worldwide. The disease is often difficult to detect in its early stages, leaving many patients with an undiagnosed and progressive condition. According to an article in The Lancet (Mark et al., 2025), an estimated 788 million people globally are living with chronic kidney disease.
"These new research findings further strengthen our position within fibrotic diseases while opening the door to a large and growing patient population with significant unmet medical needs. We look forward to advancing the development toward new therapeutic opportunities," said Johan Emilsson, CEO of Sprint Bioscience.
About Chronic Kidney Disease (CKD)
CKD is a long-term and often progressive reduction of kidney function, commonly caused by diabetes or hypertension. Despite its high prevalence, there are currently no approved treatments that directly target the underlying disease mechanisms, including fibrosis (scar tissue formation) in kidney tissue. Current medical care primarily focuses on slowing disease progression by controlling blood pressure and blood glucose levels. There is therefore a substantial unmet medical need for therapies that can reduce fibrosis, preserve kidney function, and prevent or delay the need for dialysis or transplantation. CKD is relatively common, affecting approximately 10 percent of the global population.
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.
